Clinical trials: Hepatitis C, completed
Chronic Hepatitis C Infection
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
The purpose of this study is to study the effects of valacyclovir on patients who have hepatitis C and antibodies to herpes simplex type-2. Herpes simplex type 2 is a virus which causes genital herpes.
- Trial name
- NCT01453075
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Hepatitis C, Cirrhosis
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection.
- Conditions
- Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
- Trial name
- NCT01687257
- Testing
- SOF, RBV
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Hepatitis C, Kidney Transplant; Complications
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
- Conditions
- Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
- Trial name
- NCT04508907
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mayo Clinic
HIV, Hepatitis C
A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
The CTSI-PLACE Study is a study for men and women with HIV/hepatitis C co-infection or HIV only. The study looks at the impact of having hepatitis C virus in addition to HIV on risk for cardiovascular disease.
- Trial name
- CTSI-PLACE (NCT02597790)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of California, Los Angeles
Hepatocellular Carcinoma, HIV
Hepatocellular Carcinoma in HIV-infected Patients
Observational study. All HIV-infected patients who have been diagnosed of hepatocellular carcinoma (HCC), following the American Association for the Study of Liver Diseases (AASLD) criteria, in the participant centers are…
- Conditions
- Hepatocellular Carcinoma, HIV, Chronic Hepatitis C, Hepatitis B Virus
- Trial name
- GEHEP-002 (NCT02785835)
- Where
- 30 sites in Spain
- Volunteers
- 477 people
- Sponsor
- Hospital Universitario de Valme
Chronic Hepatitis C
The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection
The primary objective of this study is to evaluate the effectiveness of TCM-700C as an add-on treatment to the combination drug therapy (Peginterferon α-2b plus Ribavirin) for patients with genotype 1 chronic hepatitis C…
- Trial name
- TCM-700C (NCT00556504)
- Testing
- TCM-700C, Peginterferon alfa-2a, Ribavirin
- Where
- Taiwan
- Volunteers
- 84 people
- Sponsor
- TCM Biotech International Corp.
HCV Infection
Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)
The overall study design includes two parts, Part A and Part B. Part A evaluated ANA773 following oral administration to healthy volunteers. A total of 40 evaluable healthy volunteers were enrolled in Part A of the study.
- Trial name
- NCT01211626
- Testing
- ANA773
- Where
- 3 sites in Netherlands
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Acute
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or…
- Trial name
- TARGET3D (NCT02634008)
- Testing
- Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin
- Where
- 11 sites in Australia, New Zealand and 1 more
- Volunteers
- 83 people
- Sponsor
- Kirby Institute
Hepatitis c
Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C
Hepatitis C infects as many as 300,000 Canadians. Up to 25% of those infected will develop cirrhosis and be at risk for liver failure and liver cancer.
- Trial name
- NCT00203606
- Testing
- pegylated interferon alfa-2a ( Roche) and ribavirin
- Where
- 2 sites in Canada
- Volunteers
- 66 people
- Sponsor
- University of Calgary
Hepatitis C, Chronic
A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection
The purpose of this study is to assess the effect of telaprevir on early hepatitis (inflammation of the liver) C virus (HCV) viral kinetics in treatment-naive participants who are chronically (lasting a long time) infected with…
- Trial name
- NCT00561015
- Testing
- Telaprevir, Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
- Where
- 7 sites in France, Sweden and 1 more
- Volunteers
- 52 people
- Sponsor
- Tibotec BVBA
Hepatitis C
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein (NS5A) resistance-associated variants.
- Trial name
- NCT03004625
- Testing
- daclatasvir, asunaprevir, Ribavirin
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C
PoC-HCV Genedrive Viral Detection Assay Validation Study
The principal objective is to assess the diagnostic accuracy of the PoC assay (Genedrive, Epistem) to detect HCV RNA against the reference standard of commercial real-time polymerase chain reaction (RT-PCR) assay (RealTime HCV…
- Trial name
- NCT02992184
- Testing
- HCV RNA detection with Genedrive assay, HCV RNA detection with RealTime HCV
- Volunteers
- 417 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Cirrhosis
Transplant-Related Accelerated Progression of Hepatitis C
This study will explore why severe scarring of the liver (cirrhosis) develops so rapidly in hepatitis C-infected patients who have had a liver transplant and possibly in kidney transplant patients as well.
- Trial name
- NCT00368225
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatitis C, Treatment Naïve, Genotype 1 Patients
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study with 3 dose levels of IMO-2125 in combination with standard weight based ribavirin (investigational treatment arm) or placebo in combination with…
- Trial name
- NCT00990938
- Testing
- IMO-2125, Saline
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Hepatitis C, Substance Use Disorders
HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention
People who inject drugs (PWID) represent the overwhelming majority of both HCV and HIV/HCV infected people in the United States.
- Trial name
- NCT03242655
- Testing
- HCV GET-Up (Group Evaluation and Treatment Uptake)
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
HCV Infection
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
The purpose of this study is to determine whether a 3-day course of therapy with orally administered VCH-916 given at different dosages can effectively reduce the amount of circulating virus (i.e., viral load) in patients with…
- Trial name
- NCT00623649
- Testing
- VCH 916
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C
Plasma MicroRNA for Prediction of Hepatocellular Carcinoma
100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78).
- Trial name
- NCT05449847
- Testing
- Blood Sampling
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Benha University
HIV Infections, HCV
An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals
This study will determine if Albumin-linked interferon (Albinterferon alfa-2b) every 2 weeks is safe and tolerated by patients infected by both hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
- Trial name
- NCT00489385
- Testing
- Albinterferon, Ribavirin, Albuferon
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.
- Trial name
- NCT00088140
- Testing
- IDN-6556
- Where
- 15 sites in United States
- Volunteers
- 204 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.